Last reviewed · How we verify
A Randomized, Placebo-Controlled, Phase IIb Study of CYT003-QbG10 (CYT003), a TLR9 Agonist, in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids
A phase IIb study in patients to evaluate CYT003- QbG10 versus placebo, in patients with mild to moderate allergic asthma not sufficiently controlled on inhaled steroid. Altogether 170 patients, randomized to two treatment groups will be included. Key outcome measures are patient reported parameters on their asthma
Details
| Lead sponsor | Cytos Biotechnology AG |
|---|---|
| Phase | Phase 2 |
| Status | WITHDRAWN |
| Start date | 2014-05 |
Conditions
- Asthma
Interventions
- CYT003
- Placebo
Primary outcomes
- Asthma Control Questionnaire (ACQ) — 12 weeks
Countries
United States